Drug combination reduces polyps for patients with inherited disorder and high risk for colorectal cancer

In a study appearing in the March 22/29 issue of JAMA, Deborah W. Neklason, Ph.D., of the Huntsman Cancer Institute, University of Utah, Salt Lake City, and colleagues randomly assigned 92 patients with familial adenomatous polyposis to the drugs sulindac twice daily and erlotinib daily (n = 46) or placebo (n = 46) for 6 months.